Share price
₹147 latest close · −3.6% over the last 90 sessions
₹147 month-end · −20.7% over 12 months
₹147 month-end · −31.0% since Feb '25
52-week range ₹131.16 to ₹234.00 · 1-year volatility 50.6%
How rough has the ride been?
Drawdown from peak
Largest drawdowns
-51.8% (2025-09 peak to 2026-11 low, not yet recovered)
-33.2% (2025-02 peak to 2025-03 low, recovered 2025-06)
-26.2% (2025-06 peak to 2025-09 low, recovered 2025-09)
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- ROCE5th▼ 6 pts vs a year ago
- Op. margin10thflat vs a year ago
- Revenue growth38th
- EPS growth1st
- Debt/equity ↓7thflat vs a year ago
- Cash cycle ↓91st▲ 18 pts vs a year ago
- P/E ↓3rd
- 12M momentum16th
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What is the price implying?
Trailing earnings per share are negative, so a P/E-based figure does not exist. See the loss-makers list on the Expectations Gap page for a revenue-based version.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What prices imply across Health Technology The market-wide Expectations lists
Key figures
- Share Priceclose 9 Nov
- ₹147.00
- ROCE
- -5.0%
- Market Cap
- ₹153 cr
- Revenue (TTM)
- ₹191 cr
- P/S
- 0.8x
- P/B
- 0.9x
- ROE
- -11.1%
- Operating Margin
- 2.3%
- Debt / Equity
- 0.9x
- Promoter Holding
- 50.9%
- 12M Momentum
- -20.7%
52-week range
Price risk
Balance sheet & cash
Are profits backed by cash?
Other income reliance—Not enough data
Not enough reported data to compute this.
Tax rate—Not enough data
Not enough reported data to compute this.
Cash conversion—Not enough data
Not enough reported data to compute this.
Free cash flow0 of 5 yrsBeyond threshold
Fiscal years with positive free cash flow in the last 5: 0. Bands: at least 80% of years, 40% to 80%, below 40%.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress1% of fixed assetsWithin range
Capital work-in-progress is 1% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
Who has been buying and selling?
- Over 2 years, promoters trimmed 0.7 pts.
- The number of shareholders fell from 9,862 to 8,756 (-11%) between Sep 2024 and Jun 2026.
Holdings, Jun '26
How each group changed
Number of shareholders
Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.
What happened next to similar setups
- We found 50 past situations where a non-financial company looked like NATURAL CAPSULES LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
- Over the following 12 months the middle half of them returned −18% to +48% vs the market, against −4% for all non-financial companies in the same months.
- The analogs' median sat above that base rate (gap +5.2%, 80% range +1.3% to +15.6%), but the matches cluster in only 6 distinct 12-month windows.
Where the 50 outcomes landed
Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 5 beyond the range shown, drawn at the edge
50 past situations · 50 companies · 37 months · 2020–2025
The closest matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| NITCO Producer Manufacturing |
Jun 2022 | — | -11% | −16% | −43% | −35% |
| RAMANEWS Process Industries |
Jan 2022 | — | -5% | +34% | −23% | −27% |
| ELGIRUBCO Producer Manufacturing |
Jan 2020 | — | 0% | −22% | −31% | +44% |
| SPLIL Consumer Non-Durables |
Sep 2020 | — | -35% | −17% | −35% | +5% |
| MUKTAARTS Technology Services |
Oct 2023 | — | -3% | +23% | −21% | −17% |
Show the other 3 matches
| Company | When | P/E | ROCE | 12M mom. | Drawdown | Next 12 months |
|---|---|---|---|---|---|---|
| DELTAMAGNT Producer Manufacturing |
Jun 2024 | — | -7% | +25% | −16% | −2% |
| NIBL Producer Manufacturing |
Dec 2022 | — | -2% | −11% | −36% | +60% |
| BANKA Industrial Services |
Jun 2025 | — | -8% | −23% | −48% | +29% |
How reliable is this?
Matched on P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and interest cover. Not used (unavailable for this company): P/E. This company is loss-making, so it was only compared with loss-making companies. One match per company and at most 7 from any one month.
Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.
What changed?
10 events since Mar '25
- NovPriceFell 52% from the Sep 2025 peak to the Nov 2026 low.
- JunResultsRevenue (TTM) reached a new high of ₹187 cr.
- FebSharesShare count is up 11.1% over 12 months.
- SepResultsEPS (TTM) turned negative.
- SepPriceRegained the 2025-06 peak, 0 months after the low.
- SepPriceFell 26% from the Jun 2025 peak to the Sep 2025 low.
- SepPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
- JunPriceRegained the 2025-02 peak, 3 months after the low.
Show 2 earlier events
- MarPriceFell 33% from the Feb 2025 peak to the Mar 2025 low.
- MarPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history22 months · 2025-02 to 2026-11
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-11 | — | ₹191 cr | -11.1% | -5.0% | 0.9x |
| 2026-10 | — | ₹191 cr | -11.1% | -5.0% | 0.9x |
| 2026-09 | — | ₹191 cr | -11.1% | -5.0% | 0.9x |
| 2026-08 | — | ₹187 cr | -11.0% | -5.0% | 0.9x |
| 2026-07 | — | ₹187 cr | -11.0% | -5.0% | 0.9x |
| 2026-06 | — | ₹187 cr | -11.0% | -5.0% | 0.9x |
| 2026-05 | — | ₹174 cr | -8.0% | 3.0% | 0.8x |
| 2026-04 | — | ₹174 cr | -8.0% | 3.0% | 0.8x |
| 2026-03 | — | ₹174 cr | -8.0% | 3.0% | 0.8x |
| 2026-02 | — | ₹180 cr | -5.0% | 3.0% | 0.8x |
| 2026-01 | — | ₹180 cr | -5.0% | 3.0% | 0.8x |
| 2025-12 | — | ₹180 cr | -5.0% | 3.0% | 0.8x |
| 2025-11 | — | ₹175 cr | -2.3% | 3.0% | 0.8x |
| 2025-10 | — | ₹175 cr | -2.3% | 3.0% | 0.8x |
| 2025-09 | — | ₹175 cr | -2.3% | 3.0% | 0.8x |
| 2025-08 | 393.0x | ₹169 cr | 0.3% | 3.0% | 0.8x |
| 2025-07 | 425.0x | ₹169 cr | 0.3% | 3.0% | 0.8x |
| 2025-06 | 437.7x | ₹169 cr | 0.3% | 3.0% | 0.8x |
| 2025-05 | 184.6x | ₹164 cr | 0.5% | 5.0% | 0.5x |
| 2025-04 | 168.6x | ₹164 cr | 0.5% | 5.0% | 0.5x |
| 2025-03 | 154.8x | ₹164 cr | 0.5% | 5.0% | 0.5x |
| 2025-02 | 89.6x | ₹161 cr | 1.1% | 5.0% | 0.5x |